Skip to main content
Figure 5 | Journal of Hematology & Oncology

Figure 5

From: Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells

Figure 5

Effect of TG101348 on HS-5 cells. (A) HS-5 cells were cultured in the presence of different concentrations of TG101348 for 24 h, and total extracts were examined by immunoblotting using anti-phospho STAT5, STAT5, and β-actin Abs. Blots were scanned and optical densities were determined using ImageJ software. (B) HS-5 cells were treated with TG101348 for 24 h and conditioned medium was collected. The relative levels of 36 different cytokines were analyzed using the Human Cytokine Array Kit. The expression of cytokines was determined using ImageJ software. Results are representative of three separate experiments. *p < 0.05, TG101348 treatment vs. control.

Back to article page